Axsome Therapeutics, Inc. or CRISPR Therapeutics AG: Who Manages SG&A Costs Better?

Managing SG&A Costs: Axsome vs. CRISPR

In the competitive landscape of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for sustaining growth and innovation. Axsome Therapeutics, Inc. and CRISPR Therapeutics AG, two prominent players in the field, have shown contrasting trends in their SG&A expenditures over the past decade.

A Decade of Financial Strategy

From 2014 to 2023, Axsome Therapeutics has seen a staggering increase in SG&A costs, rising from a modest $1.4 million to over $323 million. This represents a growth of over 23,000%, reflecting their aggressive expansion and investment in administrative capabilities. In contrast, CRISPR Therapeutics AG has maintained a more stable trajectory, with expenses peaking at approximately $102 million in 2021 before declining to $76 million in 2023.

Strategic Implications

While Axsome's rapid increase in SG&A costs may indicate robust growth strategies, CRISPR's more controlled spending could suggest a focus on efficiency and cost management. Investors and stakeholders should consider these trends when evaluating the long-term sustainability and strategic direction of these companies.